The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with ...

Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure ...

Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions.

U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Nearly 4.4 million adult New Yorkers, or 30%, have obesity, but access to weight-loss medications varies based on a variety ...

Dandelion Health used data from medical records and artificial intelligence and found that Wegovy can help prevent 34,000 strokes and heart attacks annually in the United States.

This summary highlights major health news, including EU's endorsement of Novo Nordisk's Wegovy for heart conditions in ...

Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare ...

Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart ...

Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...

Some people may be eligible for Medicare coverage for Wegovy if they meet medical criteria for heart disease risk. However, Medicare does not cover medications that are strictly for weight management.

Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a ...